Sector News

Upstart Blade nabs BMS research executive as new R&D lead

August 21, 2017
Life sciences

Blade Therapeutics is looking to sharpen its focus after hiring Bristol-Myers Squibb’s former fibrosis research lead as its new EVP of research.

The biotech, which is working on antifibrotic (scarring) therapies, has appointed Maria E. Fuentes, Ph.D., to lead its antifibrotic programs in preclinical testing.

Blade’s flagship program, focused on a small molecule cysteine protease inhibitor, is expected to enter IND-enabling studies by year-end 2017.

Fuentes comes to the small, private biotech from Big Pharma Bristol-Myers, where she was group director of fibrosis discovery biology.

There, she was working getting into the clinic small molecules and antibody therapeutics for the treatment of fibrotic diseases, including interstitial pulmonary fibrosis (IPF) and nonalcoholic steatohepatitis (NASH).

She’s also had a stint at oncology giant Roche, making this a big coup for such a small and embryonic biotech, and following the pattern in recent years of Big Pharma executives moving into smaller biotechs.

As with many biopharmas, including Gilead, Shire, Intercept and Genfit, BMS is looking to jump into the NASH space, which could be worth tens of billions of dollars in the next decade, to help treat liver scarring and other damage caused by a buildup of fat in the liver associated specifically with obesity.

Back in April, a phase 2 trial of its NASH candidate BMS-986036 met its primary endpoint, showing a reduction of liver fat, as it battles to be one of the first to market a new medication for the condition.

“We are excited to further expand our leadership team and to welcome an accomplished executive with a proven record of advancing promising candidates into the clinic,” said Blade’s CEO Wendye Robbins, M.D.

“We believe Maria’s expertise and insights will contribute greatly to the continued momentum of our lead development programs.”

By Ben Adams

Source: Fierce Biotech

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.